• Clinical science

Disorders of sex development

Abstract

Disorders of sex development are a group of congenital conditions that affect the development of the chromosomal, gonadal, or phenotypic sex. The underlying genetic mutations affect the number and function of sex chromosomes (e.g., in Turner syndrome), lead to structural changes with altered sensitivity of hormone receptors (e.g., androgen insensitivity syndrome), or alter the function of enzymes responsible for sex hormone synthesis (e.g., congenital adrenal hyperplasia). The most characteristic clinical feature is the development of a sexual phenotype which does not correspond to the sexual genotype. Other common features include reduced fertility or infertility and concomitant organ malformations (e.g., cardiac abnormalities). Disorders of sex development can also present with difficulties in gender identification and cause considerable psychological distress. The diagnosis of these conditions is based on characteristic clinical features, evaluation of hormone levels, and genetic testing. Management includes hormone substitution, possibly sex reassignment surgery, and psychological counseling.

Congenital adrenal hyperplasia

Androgen insensitivity syndrome

  • Etiology: X-linked recessive mutation of the gene locus encoding the androgen receptor → varying degrees of end-organ insensitivity to androgens
  • Karyotype: 46,XY
  • Clinical features
    • Complete androgen insensitivity
      • Female external genitalia (testicular feminization) and physique
      • Blind-ended vaginal pouch, uterine agenesis
      • Scant or missing pubic hair
      • Primary amenorrhea, infertility (no menarche)
    • Partial androgen insensitivity: variations in phenotype, depending on the degree of androgen insensitivity
    • Male internal genitalia
    • Detection of abdominal/inguinal masses in newbornsintra-abdominal localization of undescended testicles
  • Diagnostics
  • Therapy
    • Management depends on receptor status and, especially, on the phenotype and gender identity of the affected patient.
    • Hormone treatment
    • Gonadectomy for intra-abdominal testicles typically performed after puberty (high risk of malignancy)
    • Psychological support

References:[1]

5-alpha-reductase deficiency

  • Synonym: pseudovaginal perineoscrotal hypospadias (PPSH)
  • Etiology: rare autosomal recessive loss-of-function mutation of chromosome 2
  • Karyotype: 46,XY
  • Pathophysiology
    • Normal testosterone production
    • Defective 5-alpha-reductase: testosterone not converted into dihydrotestosterone (DHT)DHT-dependent virilization of genitalia does not occur
  • Clinical features
    • Female external genitalia at birth, sometimes with pseudovaginal perineoscrotal hypospadias
    • Internal urogenital organs are male
    • In puberty, increasing synthesis of testosterone leads to virilization (phallic growth, testicular descent, development of male gender identity).
  • Diagnostics
  • Therapy
    • Female gender identity: gonadectomy; estrogen substitution therapy upon completion of longitudinal growth
    • Male gender identity: testosterone substitution

References:[2][3]

Klinefelter syndrome

  • Karyotype: 47 XXY, rarely 48 XXXY and 48 XXYY
  • Incidence: approximately 1:600 children
  • Etiology: most commonly due to nondisjunction of sex chromosomes during meiosis of parental germ cells
  • Clinical features
  • Diagnostics: : primarily a clinical diagnosis; karyotyping confirms the diagnosis
  • Complications: Increased risk of breast cancer development due to decreased levels of testosterone and increased levels of estrogen.
  • Therapy: life-long testosterone substitution

References:[4][5]

Turner syndrome

References:[4][6][7][8][9][10][11]

Swyer syndrome

  • Karyotype: 46 XY
  • Pathophysiology: normal development until the 8th embryonic week → SRY gene mutation gonads do not develop into testes → no production of testosterone and anti-Müllerian hormone (AMH) → male genital organs do not develop → uterus and vagina develop despite the presence of XY chromosomes
  • Clinical features
  • Therapy
    • Lifelong estrogen and progestogen substitution
    • Removal of streak gonads

References:[12][13][14]

Pure gonadal dysgenesis

References:[15]

Aromatase deficiency

  • Karyotype: 46 XX or 46 XY (normal sex development)
  • Pathophysiology: : Mutations in the CYP19A1 gene which encodes for the enzyme aromatase ↓ serum estrogen and ↑ serum testosterone
  • Clinical features
  • Treatment
    • Estrogen and progesterone replacement therapy
    • Calcium and vitamin D supplementation
    • Surgical correction of ambiguous genitalia

References:[16][17]

Ovotesticular disorder of sex development

  • Karyotype
    • Typically normal (46 XX > 46 XY)
    • Mosaicism (is also possible
  • Incidence: rare
  • Pathophysiology
    • Both ovarian and testicular tissue are present (true hermaphroditism)
      • Bilateral (50%) or unilateral (20%) ovotestes
        • The descent and position of the ovotestes depends on the amount of testicular tissue present in the ovotestes
          • 50% are found intra-abdominally
          • 25% in the inguinal region
          • 25% in the labio-scrotal region
      • Unilateral testes and contralateral ovary (30%)
    • The type of internal genitalia depends on the nature of the adjacent gonad
      • Fallopian tube develops beside the ovary and vas deferens with an epididymis develops beside the testicle
      • In the case of ovotestes, fallopian tubes develop in 60–70% of cases
      • A uterus can develop in the case of a unilateral ovotestis with a contralateral ovary
  • Clinical features

  • 1. Hiort O, Snyder PJ, Matsumoto AM, Geffner ME, Martin KA. Diagnosis and Treatment of Disorders of the Androgen Receptor. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/diagnosis-and-treatment-of-disorders-of-the-androgen-receptor. Last updated April 17, 2017. Accessed September 10, 2017.
  • 2. Hiort O, Snyder PJ, Matsumoto AM, Martin KA. Steroid 5-Alpha-Reductase 2 Deficiency. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/steroid-5-alpha-reductase-2-deficiency. Last updated November 10, 2015. Accessed September 10, 2017.
  • 3. Isfort AH, Hoffman RP. 5-Alpha-Reductase Deficiency . In: 5-Alpha-Reductase Deficiency . New York, NY: WebMD. http://emedicine.medscape.com/article/924291. Updated November 11, 2016. Accessed September 10, 2017.
  • 4. Le T, Bhushan V, Bagga HS. First Aid for the USMLE Step 2 CK. McGraw-Hill Medical; 2009.
  • 5. Defendi GL, Rohena LO. Klinefelter Syndrome. In: Klinefelter Syndrome. New York, NY: WebMD. http://emedicine.medscape.com/article/945649. Updated April 20, 2017. Accessed September 10, 2017.
  • 6. Daniel MS, Rohena LO. Turner Syndrome. In: Turner Syndrome. New York, NY: WebMD. http://emedicine.medscape.com/article/949681. Updated June 17, 2016. Accessed February 19, 2017.
  • 7. Backeljauw P. Clinical Manifestations and Diagnosis of Turner Syndrome. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-turner-syndrome. Last updated May 23, 2018. Accessed May 28, 2018.
  • 8. De Groote K, Demulier L, De Backer J, et al. Arterial hypertension in Turner syndrome. J Hypertens. 2015: p. 1. doi: 10.1097/hjh.0000000000000599.
  • 9. Backeljauw P. Management of Turner Syndrome. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/management-of-turner-syndrome. Last updated December 13, 2017. Accessed May 28, 2018.
  • 10. Stochholm K, Juul S, Juel K, Naeraa RW, Højbjerg Gravholt C. Prevalence, incidence, diagnostic delay, and mortality in Turner syndrome. Send to J Clin Endocrinol Metab. 2006; 91(10): pp. 3897–3902. doi: 10.1210/jc.2006-0558.
  • 11. Elsheikh M, Dunger DB, Conway GS, Wass JAH. Turner’s syndrome in adulthood. Endocr Rev. 2002; 23(1): pp. 120–140. doi: 10.1210/edrv.23.1.0457.
  • 12. Baron J, Warenik-Szymankiewicz A, Miedzianowski J, Baron JJ. New aspects of diagnosing and treating pure gonadal dysgenesis 46XY and 46XX. Endokrynol Pol. 1993; 44(4): pp. 483–496. pmid: 8055817.
  • 13. Lifshitz F. Pediatric Endocrinology . New York, NY: Informa Healthcare USA, Inc.; 2007.
  • 14. King TFJ, Conway GS. Swyer syndrome. Send to Curr Opin Endocrinol Diabetes Obes. 2014; 21(6): pp. 504–510. doi: 10.1097/med.0000000000000113.
  • 15. Pertusa S, Palacios A. 46 XX pure gonadal dysgenesis: an infrequent cause of primary amenorrhoea. BMJ Case Rep. 2009. doi: 10.1136/bcr.07.2008.0485.
  • 16. Le T, Bhushan V, Sochat M, Petersen M, Micevic G, Kallianos K. First Aid for the USMLE Step 1 2014. McGraw-Hill Medical; 2014.
  • 17. Carani C, Rochira V. Aromatase Deficiency. http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=GB&Expert=91. Updated April 1, 2013. Accessed September 10, 2017.
  • Ceci M, Calleja E, Said E, Gatt N. A case of true hermaphroditism presenting as a testicular tumour. Case Rep Urol. 2015; 2015: p. 598138. doi: 10.1155/2015/598138.
  • Le T, Bhushan V,‎ Sochat M, Chavda Y, Zureick A. First Aid for the USMLE Step 1 2018. New York, NY: McGraw-Hill Medical; 2017.
  • Dayal MB. Ovotesticular Disorder of Sexual Development. In: Scott Lucidi R. Ovotesticular Disorder of Sexual Development. New York, NY: WebMD. https://emedicine.medscape.com/article/256289. Updated January 12, 2017. Accessed November 17, 2018.
last updated 11/17/2018
{{uncollapseSections(['ljcv0c0', 'AkcRqc0', '_kc5qc0', 'zkcrqc0', 'sjctbc0', 'HjcKbc0', 'rjcfbc0', '7jc4bc0', 'ELc8z10', 'IxcYBe0'])}}